Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.365 USD | -3.41% | -7.87% | +158.98% |
05-28 | Johnson & Johnson Acquires Experimental Eczema Drug for $1.25 Billion | MT |
05-15 | Needham Adjusts Price Target on Arcutis Biotherapeutics to $18 From $16, Maintains Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+158.98% | 1B | |
+11.91% | 114B | |
+11.60% | 105B | |
-4.68% | 23.83B | |
-0.82% | 21.73B | |
-10.12% | 18.1B | |
-42.12% | 16.34B | |
-17.47% | 16.13B | |
+2.77% | 13.75B | |
+34.58% | 11.76B |
- Stock Market
- Equities
- ARQT Stock
- News Arcutis Biotherapeutics, Inc.
- Earnings Flash (ARQT) ARCUTIS BIOTHERAPEUTICS Posts Q1 Revenue $49.6M